Kalaris Therapeutics

Kalaris Therapeutics

Yahoo Finance • 26 days ago

KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) Stockholders

STAMFORD, Conn., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating potential legal claims on behalf of stockholders of Kalaris Therapeutics, Inc. (Nasdaq: KLRS), formerly AlloVir, Inc. (Nasdaq: ALVR), who have continu... Full story

Yahoo Finance • last month

Kalaris appoints Liisa Bayko as CFO

* Kalaris Therapeutics (KLRS [https://seekingalpha.com/symbol/KLRS]) has appointed Liisa Bayko as chief financial officer, the company said on Monday. * Bayko brings more than two decades of experience in biotechnology finance, strateg... Full story

Yahoo Finance • last month

Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts

Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts Enrollment in the Phase 1b/2 multiple-ascending dose trial of TH103 continues, with prelimi... Full story

Yahoo Finance • 2 months ago

Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

BERKELEY HEIGHTS, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent re... Full story

Yahoo Finance • 8 months ago

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent re... Full story

Yahoo Finance • 11 months ago

UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and efficacy in nAMD patients receiving four initial monthly doses of TH103 Phase 1b/2 study to inform dose selection for potential Phase 3 development... Full story

Yahoo Finance • last year

Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates

Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the re... Full story

Yahoo Finance • last year

Piper Sandler assumes coverage of Kalaris stock with Neutral rating

Investing.com - Piper Sandler has initiated coverage of Kalaris (NASDAQ:KLRS) with a Neutral rating and a $3.00 price target. The micro-cap biotech company, currently valued at $48 million, has seen its shares decline by roughly 78% over t... Full story

Yahoo Finance • last year

Kalaris stock rating reiterated at Outperform by William Blair

Investing.com - William Blair has reiterated an Outperform rating on Kalaris (NASDAQ:KLRS), maintaining its positive outlook on the biopharmaceutical company focused on treating neovascular retinal diseases. The company, currently valued a... Full story

Yahoo Finance • last year

Bernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. Securities

BOSTON, June 05, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of a proposed class action settlement that would b... Full story

Yahoo Finance • last year

Kalaris to Participate at Stifel Ophthalmology Forum

PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal... Full story

Yahoo Finance • last year

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the reti... Full story

Yahoo Finance • last year

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

PALO ALTO, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retina... Full story